Cohesive Technologies, Inc. v. Waters Corp.

543 F.3d 1351, 88 U.S.P.Q. 2d (BNA) 1903, 2008 U.S. App. LEXIS 21013, 2008 WL 4472884
CourtCourt of Appeals for the Federal Circuit
DecidedOctober 7, 2008
Docket2008-1029, 2008-1030, 2008-1031, 2008-1032, 2008-1059
StatusPublished
Cited by112 cases

This text of 543 F.3d 1351 (Cohesive Technologies, Inc. v. Waters Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cohesive Technologies, Inc. v. Waters Corp., 543 F.3d 1351, 88 U.S.P.Q. 2d (BNA) 1903, 2008 U.S. App. LEXIS 21013, 2008 WL 4472884 (Fed. Cir. 2008).

Opinions

Dissenting opinion filed by Circuit Judge MAYER.

[1357]*1357LINN, Circuit Judge.

This is a patent infringement case. Cohesive Technologies, Inc. (“Cohesive”) brought three related actions accusing Waters Corporation (“Waters”) of infringing U.S. Patent No. 5,772,874 (the “'874 patent”) and U.S. Patent No. 5,919,368 (the “ '368 patent”). In the first action, No. 98-CV-12308, Cohesive accused Waters’s 30 p,m Oasis high-performance liquid chromatography (“HPLC”) columns (the “30 ixm columns”) of infringing the '874 patent. See Cohesive Techs., Inc. v. Waters Corp., 526 F.Supp.2d 84, 88 (D.Mass.2007). In the second action, No. 99-CV-11528, Cohesive accused the same 30 |rm columns of infringing the '368 patent. See id. In the third action, No. 01-CV-12307, Cohesive accused Waters’s 25 |xm Oasis HPLC columns (the “25 |xm columns”) of infringing both patents. See id.

A jury in the first action found that the '874 patent was not invalid, and that the 30 ixm columns infringed the '874 patent. See id. The district court then held a combined bench trial and hearing on damages, willful infringement, and inequitable conduct in the first action, and on preliminary injunction and summary judgment motions in the second and third actions. The district court entered judgment in favor of Cohesive in the first action, granted Cohesive’s motion for summary judgment of infringement and no invalidity in the second action, and awarded damages. Id. at 126. However, in the third action, the district court granted Waters’s motion for summary judgment of noninfringement, concluding that the 25 |xm products did not infringe either patent. Id. Both parties appeal numerous aspects of the judgment.

As to the 30 |xm products, we conclude that the district court correctly construed the term “rigid” and properly denied Waters’s motion for judgment of noninfringement as a matter of law. We further conclude that the district court committed no clear error in concluding that Waters failed to prove the deceptive intent necessary to sustain its claim of inequitable conduct. However, we agree with Waters that the district court was wrong to enter judgment as a matter of law on anticipation without submitting the issue to the jury-

As to the 25 p,m products, we disagree with the district court’s construction of “greater than about 30 p,m.” Under the correct construction, Waters was not entitled to summary judgment of no literal infringement. The district court was, however, correct to grant Waters’s motion for summary judgment of no infringement under the doctrine of equivalents, though not for the reasons that the district court articulated.

As to damages, because the district court incorrectly considered the 25 |xm product as an acceptable noninfringing substitute, and because it is unclear whether the other available product, standing alone, would have been an acceptable substitute, we vacate the district court’s judgment that Cohesive was not entitled to lost profits and remand for reconsideration by the district court in the first instance. We find no clear error in the district court’s conclusion that Waters’s infringement was not willful. Finally, we decline Cohesive’s request to assign this matter to a different district court judge on remand. Accordingly, we affirm-in-part, reverse-in-part, vacate-in-part, and remand.

I. BACKGROUND

The '874 and '368 patents both relate to HPLC. HPLC is a process for separating, [1358]*1358identifying, and measuring compounds contained in a liquid. Pharmaceutical companies often use HPLC in drug testing to separate absorbed compounds from blood. In HPLC, a liquid containing the compounds to be measured is passed under pressure through a packed column of chromatographically active particles. See '874 patent col.l 11.24-28. Because the different molecular components in the liquid have different affinities for the particles in the column, each component is extracted from the liquid at a different rate and, therefore, at a different location along the column. See id. col.l 11.28-32. The effectiveness of HPLC at separating molecules from the liquid depends on several variables, including the size and structure of the particles in the column. See id. col.2 11.3-19.

The '368 patent issued from a divisional application of the application that resulted in the '874 patent, and the patents share the same specification. Cohesive asserted claims 1, 3, 7, 9, 15, 16, and 20 of the '874 patent and claims 1, 3, and 8 of the '368 patent. See Cohesive, 526 F.Supp.2d at 107. Claim 1 of the '874 patent recites:

Chromatography apparatus comprising, in combination,

a chromatographic body formed as a substantially uniformly distributed multiplicity of rigid, solid, porous particles with chromatographically active surfaces, said particles having average diameters of greater than about 30 pm, the interstitial volume between said particles being not less than about 45% of the total volume of said column; and
means for loading said surfaces with at least one solute that is reactive with said surfaces, by flowing a liquid mixture containing said solute through said body at a velocity sufficient to induce flow of said mixture within at least a substantial portion of said interstitial volume at a reduced velocity greater than about 5,000.

'874 patent col.20 11.20-34. Each of the asserted claims requires essentially the same two key limitations at issue in this appeal: particles that are “rigid” and have average diameters “greater than about 30 pm.” See id. col.20 11.38-42, 54-56, 60-65 (claims 3, 7, and 9 depending from claim 1); id. col.21 1.36-col.22 1.8 (claim 15 requiring “rigid solid particles” having “substantially uniform mean diameters of not less than about 30 pm”); id. col.22 11.9-21 (claim 16 requiring “rigid, solid, porous particles” with “substantially uniform average diameters in the range between about 30 to about 500 pm”); id. col.22 11.33-35 (claim 20 depending from claim 16); '368 patent col.20 11.14-28 (claim 1 requiring step of “packing ... rigid, solid, porous particles” with “average diameters of not less than about 30 pm”); id. col.20 11.32-36, 53-56 (claims 3 and 8 depending from claim l).1

Cohesive brought its first infringement action against Waters in 1998, alleging that the 30 pm columns infringed the '874 patent. In 1999, while the first action was pending, the '368 patent issued. Cohesive then filed a second infringement action against Waters, asserting that use of the same 30 pm columns infringed the method claims of the '368 patent.

In 2001, the district court held a sixteen-day jury trial in the first action. During [1359]*1359trial, Waters alleged and presented evidence that the claims of the '874 patent were anticipated by seven separate prior art references. Waters also alleged that the claims of the '874 patent were obvious, both in light of each reference independently, and in light of various combinations of the references. Over Waters’s objection, the district court chose not to submit anticipation to the jury, because Waters had alleged obviousness, and the district court “[thought] of anticipation as being a subset of obviousness.” J.A. 5710. Accordingly, the district court sua sponte entered a directed verdict in favor of Cohesive, finding that the '874 patent was not anticipated.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
543 F.3d 1351, 88 U.S.P.Q. 2d (BNA) 1903, 2008 U.S. App. LEXIS 21013, 2008 WL 4472884, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cohesive-technologies-inc-v-waters-corp-cafc-2008.